IWC - ETF AI Analysis
Top Page
iShares Micro-Cap ETF (IWC)
Rating:58Neutral
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered strong gains so far this year, indicating that its micro-cap strategy has recently worked well for investors.
Outperforming Top Holdings
Many of the largest positions, especially in health care and technology, have shown strong performance, helping support the fund’s overall returns.
Broad Sector Diversification
The ETF spreads its investments across many sectors, which helps reduce the impact if any single industry experiences a downturn.
Negative Factors
Higher Expense Ratio
The fund’s fees are relatively high compared with many broad market ETFs, which can slightly reduce long-term returns for investors.
Micro-Cap Volatility Risk
Because the ETF focuses on very small companies, its share price can be more volatile and sensitive to market stress than large-cap funds.
Heavy U.S. Concentration
Almost all of the ETF’s holdings are in U.S. companies, offering little geographic diversification if the U.S. market weakens.
IWC vs. SPDR S&P 500 ETF (SPY)
AUM1.44B
RegionNorth America
Expense Ratio0.60%
Beta1.25
IssueriShares
Inception DateAug 12, 2005
Dividend Yield0.9%
Asset ClassEquity
Index TrackedRussell Microcap
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume52,558
30 Day Avg. Volume108,767
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
286.49Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1346
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IWC Summary
The iShares Micro-Cap ETF (IWC) invests in very small U.S. companies and follows the Russell Microcap Index. It spreads money across many sectors, including health care, financials, and technology, with holdings like Bandwidth and Interface. Someone might consider IWC if they want growth potential from younger, smaller businesses and extra diversification beyond the usual large, well-known stocks. However, because these micro-cap companies are tiny and more fragile, the ETF’s price can be very volatile and may move up and down more sharply than the overall stock market.
How much will it cost me?The iShares Micro-Cap ETF (IWC) has an expense ratio of 0.6%, which means you’ll pay $6 per year for every $1,000 invested. This is higher than average because the fund is focused on micro-cap stocks, which require more active management compared to broad-market index funds. It reflects the specialized nature of the ETF and the effort involved in tracking smaller, less liquid companies.
What would affect this ETF?The iShares Micro-Cap ETF (IWC) could benefit from economic growth and innovation in sectors like healthcare and technology, which make up a significant portion of its holdings. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately affect smaller companies with limited resources. Additionally, regulatory changes or sector-specific disruptions could impact the performance of its top holdings and overall micro-cap exposure.
IWC Top 10 Holdings
IWC is a pure U.S. micro‑cap play, and its story is being written mostly by small health care and tech names. CareDx and Nurix Therapeutics have been rising, giving the fund a helpful lift as their turnaround and growth narratives gain traction. Bandwidth has also been climbing, adding some tech spice to returns. On the flip side, MBX Biosciences and SELLAS Life Sciences feel more like dead weight, with financial strains keeping their stocks lagging. With no single giant in charge, performance is driven by a broad cast of tiny, volatile players.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Penguin Solutions | 0.61% | $8.80M | $2.64B | 130.73% | 61 Neutral | |
| Nurix Therapeutics | 0.53% | $7.69M | $2.45B | 110.24% | 54 Neutral | |
| Ouster | 0.52% | $7.57M | $2.26B | 77.48% | 45 Neutral | |
| MBX Biosciences, Inc. | 0.48% | $7.02M | $3.16B | 379.49% | 38 Underperform | |
| Interface | 0.46% | $6.72M | $1.96B | 39.21% | 72 Outperform | |
| CareDx | 0.46% | $6.65M | $1.97B | 257.69% | 77 Outperform | |
| SELLAS Life Sciences Group | 0.46% | $6.60M | $1.91B | 503.01% | 43 Neutral | |
| Innodata | 0.45% | $6.51M | $1.96B | 39.76% | 67 Neutral | |
| Viridian Therapeutics | 0.42% | $6.12M | $2.20B | 8.67% | 60 Neutral | |
| Urogen Pharma | 0.41% | $5.92M | $2.00B | 97.11% | 50 Neutral |
IWC Technical Analysis
Negative
―
Price Trends
190.75
Negative
181.18
Positive
170.78
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IWC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 191.84, equal to the 50-day MA of 190.75, and equal to the 200-day MA of 170.78, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IWC.
IWC Peer Comparison
Comparison Results
Performance Comparison
IWC
iShares Micro-Cap ETF
187.65
57.58
44.27%
ONEQ
Fidelity Nasdaq Composite Index ETF
―
―
―
PRF
Invesco FTSE RAFI US 1000 ETF
―
―
―
MGC
Vanguard Mega Cap ETF
―
―
―
RWL
Invesco S&P 500 Revenue ETF
―
―
―
VFLO
VictoryShares Free Cash Flow ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents